NCT03766399View on ClinicalTrials.gov

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

PHASE1CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions
Asthma
Interventions
DRUG

AZD0449

Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.

DRUG

Placebo

Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).

Trial Locations (4)

6021

Research Site, Wellington

14050

Research Site, Berlin

HA1 3UJ

Research Site, Harrow

M23 9GP

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY